Home › Myelofibrosis › Massachusetts › Boston
Myelofibrosis clinical trials in Boston, MA
13 studies for Myelofibrosis are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
- Massachusetts General Hospital, Boston
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
RecruitingPhase 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
RecruitingPhase 3
- Tufts Medical Center, Boston
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
RecruitingPhase 1
- Site US03, Boston
- Site US12, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RecruitingPhase 2Healthy volunteers welcome
- DFCI/BWH Brigham and Women's Hospital, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
RecruitingPhase 1Healthy volunteers welcome
- Brigham and Women's Hospital, Boston
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RecruitingPhase 1/2
- Massachusetts General Hospital (Data Collection Only), Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RecruitingPhase 1
- Dana Farber Cancer Institute, Boston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
- Dana Farber Cancer Institute, Boston
Momelotinib During and After HCT in Myelofibrosis
RecruitingPhase 1
- Massachusetts General Hospital, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
- Dana-Farber Cancer Institute, Boston
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RecruitingPhase 3
- Dana Farber Cancer Institute, Boston
Myelofibrosis trials in other cities
- New York City, NY21 studies
- Houston, TX20 studies
- Durham, NC13 studies
- Columbus, OH12 studies
- Seattle, WA12 studies
- Tampa, FL11 studies
- Nashville, TN11 studies
- Miami, FL11 studies
- Salt Lake City, UT11 studies
- Ann Arbor, MI10 studies
- Atlanta, GA10 studies
- Baldwin Park, CA10 studies
Other studies in Boston
- Breast Cancer110 studies
- Cancer (all types)90 studies
- Non-Small Cell Lung Cancer87 studies
- Lung Cancer63 studies
- Colorectal Cancer62 studies
- Ovarian Cancer62 studies
- Metastatic Cancer61 studies
- Prostate Cancer56 studies
- Endometrial Cancer51 studies
- Depression50 studies
- Heart Failure46 studies
- Multiple Myeloma45 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.